On the heels of a snap $1B raise, CureVac outlines plans to seek emergency OK for Covid-19 vaccine -- shares rocket up
CureVac is going from being one of the quietest players in the race to develop a new vaccine to fight the worst public health crisis in a century to a challenger for the multibillion-dollar market that awaits the first vaccines to make it over the finish line. Typically low-key at a time of brash comments and incredibly ambitious development timelines from the leaders, CureVac now is jumping straight into the spotlight.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.